Biotech Week articles from June 2002

Biotech Week archives from June 2002

Scientists develop fully human monoclonal antibodies to PDGF D.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- CuraGen Corporation (CRGN), an integrated, genomics-based pharmaceutical company, announced that CuraGen and Abgenix scientists have successfully developed highly specific, fully human monoclonal...

Tenofovir cytotoxicity lower than that of similar agents.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The nucleoside reverse transcriptase inhibitor (NRTI) tenofovir is less toxic to cells than similar agents, researchers in the United States report. ...

Collaboration with Mount Sinai School of Medicine focused on HIV.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- AxCell Biosciences, a subsidiary of Cytogen Corporation (CYTO), announced the signing of a research collaboration with Irwin Gelman, PhD, of the Mount Sinai School of Medicine (MSSM) to identify...

Lamivudine can heighten transplacental zidovudine toxicity.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The antiretroviral agent lamivudine may increase the toxicity of zidovudine when the two drugs are used to prevent peripartum transmission of HIV, researchers...

Phase I/II clinical trial of CpG 7909 initiated.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Coley Pharmaceutical Group, Inc., announced that it has initiated a multicenter open label, phase I/II clinical trial of its lead product candidate, CpG 7909, for the treatment of patients with stage IV...

MelTec studies describe protein networks involved in T-cell invasion.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- MelTec GmbH, a functional proteomics company, announced the publication of two scientific studies in the April 2002 issue of the Journal of Theoretical Medicine, describing the protein networks involved...

INCOMIN data showing superior efficacy of Betaferon/Betaseron vs. Avonex.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Schering AG announced that the final 2-year results from INCOMIN (Independent Comparison of Interferon) study were published on April 27 in the peer-reviewed journal, The Lancet. The results show that...

Suit filed citing vaccines contained poisonous mercury.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- The law firm of Ferraro & Associates, P.A., announced it has filed one of the first mercury poisoning lawsuits in South Florida against American Home Products and its related companies. The suit...

Patent allowed for liquid form of disodium pamidronate.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners (APPX) said its wholly owned subsidiary, Pharmaceutical Partners of Canada, Inc., (PPC) has been issued a new patent in Canada entitled: "Liquid Injectable Formulation...

FDA authorizes full enrollment of TAXUS IV clinical trial.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Angiotech Pharmaceuticals, Inc., (ANPI) was notified by its corporate partner, Boston Scientific Corporation (BSC) that the U.S. Food and Drug Administration (FDA) has authorized full enrollment of...

Foznol NDA submitted to FDA.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- AnorMED, Inc., announced that its licensee, Shire Pharmaceuticals Group plc, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Foznol (likely to be renamed...

John R. Moore named as general counsel.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) announced the appointment of John R. Moore to the newly created position of vice president and general counsel, effective May 1, 2002. Moore will oversee Array's legal...

Nasal research collaboration with CIIT Centers for Health Research announced.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Bespak, the innovator of drug delivery technologies, and the CIIT Centers for Health Research, a leader in respiratory and inhalation science, have announced the initiation of a significant research...

Cryo-RECAF released for staining of cancer cells in frozen tissue sections.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- BioCurex, Inc., (BOCX) is pleased to announce the commercial launch of its second product, based on the novel and proprietary RECAF marker to the market. Cryo-RECAF is a kit designed for single patient...

BioCrine AB acquired; private financing raises $20M.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- BioStratum, Inc., a world leader in drug development based on research of the basal lamina, has closed a $20 million round of private financing. The private placement includes investors from both the...

Canadian biotech announces US$150M shelf registration.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM) announced that it has received final clearance from the applicable Canadian regulatory authorities with respect to a US$150 million shelf prospectus filed in specified Canadian...

First quarter performance involves decreased net loss.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM) reported financial results for the 3 months ended March 31, 2002. Results are reported in Canadian dollars with a March 31, 2002 rate of $1.00 Canadian equaling $0.63 U.S. ...

Company announces record-breaking first quarter 2002.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Bradley Pharmaceuticals, Inc., (BPRX) announced that net sales for the first quarter, ended March 31, 2002, totaled $9.3 million, an increase of $4.0 million, or 76% compared with net sales reported for...

Notice of allowance granted to use of PG-TXL in combination with radiation therapy.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Cell Therapeutics, Inc., (CTI) (CTIC) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for the use of polyglutamate paclitaxel (PG-TXL or CT-2103)...

Company reports net loss of $0.25 per share.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Cellegy Pharmaceuticals, Inc., (CLGY) reported that for the first quarter ended March 31, 2002, revenues were $267,000, compared with $41,000 for the same period last year. Revenues during this year's...

Worldwide patents to gene fusion system acquired.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Chemicon International, Inc., announced the acquisition of the glutathione S-transferase (GST) gene fusion system worldwide patents from Amrad Corporation, Ltd. This technology is patent protected in...

Collaboration to involve high throughput screening of Japanese compounds.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- CombinatoRx, a privately held biopharmaceutical company, announced a 3-year research collaboration with Sosei Co., Ltd., a leading Tokyo-based biopharmaceutical company, to discover novel combination...

Joann L. Data named senior vice president.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Cortex Pharmaceuticals, Inc., (COR) announced that it has appointed Joann Data, MD, PhD, to the position of senior vice president, clinical development and regulatory affairs. "Data brings to...

Q4 U.S. annual sales growth to exceed 62%.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Cyberonics, Inc., (CYBX) announced that it expects to beat its fourth quarter sales plan by a significant margin. For the fourth quarter ended April 26, 2002, record worldwide sales of Cyberonics'...

Oncosis spins off separate cellular analysis and discovery platform company Cyntellect.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Oncosis, Inc., announced it has spun-out a new company, Cyntellect, that will adapt and commercialize the laser-enabled analysis and processing (LEAP) technology platform for the life sciences and drug...

Initial public offering closes.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- DOV Pharmaceutical, Inc., (DOVP) announced the closing of its initial public offering of 5,000,000 shares of common stock, priced at $13.00 per share. CIBC World Markets Corp., Lehman Brothers,...

eResearchTechnology selected to support clinical trials.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- eResearchTechnology, Inc., (eRT), (ERES), a leading e-research technology and services provider, announced that Favrille, Inc., a San Diego based biotechnology organization, has selected eRT's eResNet...

NDA submitted for new antifungal product.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Fujisawa Healthcare, Inc., (Fujisawa) announced that a new drug application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for their antifungal product micafungin. "The...

Cutting-edge wound therapy uses subatmospheric pressure.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Continuing to enhance its clinical offering, Gentiva Health Services (GTIV), the nation's leading provider of home healthcare and specialty pharmaceutical services, announced that it has begun providing...

100 millionth treatment donated in the battle to eliminate a disease.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Pharmaceutical company GlaxoSmithKline (GSK) has announced that it has donated the first 100 million albendazole treatments as part of its commitment to the Global Alliance to Eliminate Lymphatic...

Unigene receives $3 million dollar payment for oral PTH osteoporosis program.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Unigene Laboratories, Inc., (UGNE) announced that it has received its first payment from GlaxoSmithKline (GSK) pursuant to the terms of the $150 million licensing agreement that the companies jointly...

Company announces filing of revised preliminary proxy.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- ICN Pharmaceuticals (ICN) announced that it filed its revised preliminary proxy materials with the Securities and Exchange Commission (SEC) in connection with its 2002 annual shareholders meeting. The...

Company reports 1Q record revenues.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- ICN Pharmaceuticals, Inc., (ICN) reported that first quarter revenues were a record $245.7 million compared with $199.0 million in 2001, an increase of 23%. Operating income in the first quarter was...

Keryx reports first quarter 2002 financial results.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Keryx Biopharmaceuticals, Inc., (KERX), a drug discovery company focused on developing innovative therapies for the treatment of critical medical conditions, including cancer and diabetes, released...

Screentec changes name, implements new drug discovery strategy.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Screentec BV, a Dutch life sciences company, has changed its name to Kiadis BV. The company's decision to do this signifies its progression to the next phase of its development, and underlies its...

First quarter revenue increases 136% to a record $34 million.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Kos Pharmaceuticals, Inc., (KOSP) announced financial results for the first quarter of 2002, revenue increased 136% to a record $33.9 million, up from $14.4 million for the first quarter of 2001. ...

Company completes private equity financing, announces first quarter 2002 results.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Lynx Therapeutics, Inc., (LYNX) announced it has completed an approximately $22.6 million private financing of common stock and warrants for common stock. The financing included the sale of 14.6...

President/CEO establishes trading plan.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Medarex, Inc., (MEDX) announced that Donald L. Drakeman, PhD, president and CEO of Medarex, has established a trading plan under Rule 10b5-1(c) of the Securities Exchange Act of 1934. The trading plan...

Company completes cash offer for notes assumed in COR merger.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Millennium Pharmaceuticals, Inc., (MLNM) announced that it has completed cash offers to the holders of its outstanding 4.50% convertible senior notes due June 15, 2006 and 5.00% convertible subordinated...

Ludwig Institute announce collaborative research agreement to develop MAbs.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Morphotek, Inc., and the Ludwig Institute For Cancer Research (LICR) have entered into a collaborative research and development agreement to develop therapeutic monoclonal antibodies (MAbs) and antibody...

First quarter product revenues triple over prior year.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Nanogen, Inc., (NGEN) announced its financial results for the first quarter ended March 31, 2002. Product revenues were $812,000, more than three times the total for the first quarter of 2001 of...

Company announces fourth-quarter and full-year financial results.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Northwest Biotherapeutics, Inc., (NWBT) announced financial results for the fourth-quarter and full-year ended December 31, 2001. For the fourth quarter, it reported a net loss applicable to common...

Company reports first quarter 2002 results.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Omnicare, Inc., (OCR) reported that for the 3 months ended March 31, 2002, Omnicare earned 34 cents per diluted share, excluding restructuring charges associated with the second phase of the company's...

First quarter 2002 financial results announced.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Onyx Pharmaceuticals, Inc., (ONXX) announced the results of operations for the first quarter ended March 31, 2002. The company reported a net loss of $9.8 million, or $0.53 per share for the...

Orchid enters pharmacogenomics collaboration with Merck-Medco.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Orchid BioSciences, Inc., (ORCH) announced a pharmacogenomics collaboration between its Orchid GeneShield strategic business unit and Merck-Medco, a subsidiary of Merck & Co., Inc., (MRK). Under...

$3.9M raised to develop novel multifunctional drugs.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- OxoN Medica, Inc., a privately held pharmaceutical company based in the San Francisco, California, area announced raising $3.90 million as part of its Series A financing round. OxoN develops novel...

Enrollment for MorViva clinical study completed ahead of schedule.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Pain Therapeutics, Inc., (PTIE), a medical research company, announced it has completed patient enrollment in a phase II clinical study ahead of schedule. This clinical study is designed to assess...

Japanese patent issued for Ah-IMMUNOASSAY.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Paracelsian, Inc., (PRLN) announced that the Japanese Patent Office has issued to Paracelsian Patent No. 3253300, Ah-IMMUNOASSAY methodology for the detection of dioxin and dioxin-like chemicals. ...

Paradigm reports on first quarter 2002.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Paradigm Genetics, Inc., (PDGM), an integrated life sciences company, reported that for the first quarter ended March 31, 2002, total revenues increased 8% to $5.9 million, compared with approximately...

Company reports first quarter 2002 financial results.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Penwest Pharmaceuticals Co. (PPCO) announced results for the first quarter ended March 31, 2002, which reflect the company's continued investments to expand its oral drug delivery product pipeline. ...

Par Pharmaceutical to launch flecainide acetate.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Pharmaceutical Resources, Inc., (PRX) announced its subsidiary, Par Pharmaceutical, plans to begin shipping flecainide acetate in approximately 30 days. Flecainide acetate (3M's Tambocor) is an...

Third quarter results reported.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- For the third quarter ending March 31, 2002, Pharmacyclics, Inc., (PCYC) reported a net loss of $7,896,000 or $0.49 per share, compared with a net loss of $6,639,000, or $0.41 per share, in the...

Edward F. Fritsch becomes senior vice president of development.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Phylos, Inc., announced the appointment of Edward F. Fritsch, PhD, as senior vice president of development where he will be responsible for developing a novel class of biopharmaceuticals based on the...

Douglas O. Ebersole becomes interim CEO, replacing Laurence Jay Korn.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Protein Design Labs, Inc., (PDLI) announced that Laurence Jay Korn, PhD, a cofounder of PDL and its CEO since 1987, has relinquished his responsibilities as CEO. He will continue to serve as...

Company completes discovery phase of target identification collaboration.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Rigel Pharmaceuticals, Inc., (RIGL) announced that it has delivered six additional validated drug targets to Pfizer, Inc., (PFE) thereby completing its discovery phase respiratory disease research...

U.S. FTC approves global agreement signed by Isotechnika and Roche.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Joseph Koziak, executive vice president of Isotechnika, Inc., reported that the United States Federal Trade Commission has approved the agreement for the global codevelopment of Isotechnika's transplant...

Oxaliplatin on fast track review in the U.S.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Sanofi-Synthelabo is conducting a second-line study (EFC 4584) in patients with colorectal cancer who have progressed while on/or within 6 months following treatment with irinotecan in combination with...

Santen names Adrienne Graves president and CEO.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Santen Pharmaceutical Co., Ltd., a global ophthalmic pharmaceuticals company, appointed Adrienne Graves, PhD, president and CEO of its U.S. ophthalmic business. Graves joined the Napa,...

Select Medical Corp. first quarter earnings per share up 62%.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Select Medical Corp. (SLMC) announced that for the quarter ended March 31, 2002, net operating revenues increased 20.8% to $271.9 million compared with $225.1 million for the same quarter, prior year....

SEC completes investigation of 1999 financial reporting.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Serologicals Corp. (SERO) announced that it has entered into a settlement agreement with the U.S. Securities and Exchange Commission (SEC) concluding the SEC's investigation into the company's financial...

Triangle reports financial results for first quarter 2002.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Triangle Pharmaceuticals, Inc., (VIRS) reported that for the quarter ended March 31, 2002, it had a net loss of $1,787,000, or $0.02 per share, compared with a net loss of $22,858,000, or $0.55 per...

Protonix approved for long-term treatment of Zollinger-Ellison.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Wyeth (WYE) announced that Protonix (pantoprazole sodium) Delayed-Release Tablets were approved by the U.S. Food and Drug Administration (FDA) for the long-term treatment of pathological hypersecretory...

Hirdey Bhathal tapped as new Zyomyx VP of corporate development.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Zyomyx, Inc., announced the appointment of Hirdey Bhathal, PhD, as vice president of corporate development. Bhathal will be responsible for the business development and sales of Zyomyx' protein...

Tabbiner named president and CEO; Sancilio becomes executive chairman, CSO.
June 5, 2002... 2002 JUN 5 - (NewsRx.com & NewsRx.net) -- aaiPharma, Inc., (AAII) announced that its board of directors has named Dr. Philip S. Tabbiner to the position of CEO of the company. Tabbiner succeeds Frederick D. Sancilio, PhD, who will assume...

Immunization by irradiated mosquitoes can protect against malaria.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Volunteers who underwent bites from thousands of irradiated mosquitoes harboring Plasmodium falciparum sporozoites were immunized against malaria,...

Simplified antiretroviral regimen safe, effective.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Anti-HIV maintenence therapy consisting solely of reverse transcriptase inhibitors provides benefits comparable with those of conventional regimens, with...

New experimental pill found to improve symptoms and quality of life.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, MD, acting medical...

Biotherapies' scientists identify melastatin.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Biotherapies, Inc., a biotechnology company developing new cancer therapies and diagnostic methods, announced that it has identified Melastatin, a protein that may have activity to control skin cancer....

Positive 12-month phase II results for CAT-152 reported.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Cambridge Antibody Technology announced the 12-month follow-up results from a phase II clinical trial using CAT-152 (lerdelimumab; human anti-TGFBeta2 monoclonal antibody) in patients undergoing...

Rosiglitazone reverses insulin resistance, protects against ischemic damage.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Treating obese Zucker rat hearts with rosiglitazone restored insulin sensitivity and prevented ischemic damage, sasy researchers in the U.K. ...

DC-SIGN intercellular interactions not crucial for transmission.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have cast doubt on a putative mechanism for intracellular HIV transmission. "DC-SIGN, a type II membrane-spanning C-type...

Company announces S-3 registration and purchase by institutional investors.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- AMDL, Inc., (ADL), developer and marketer of tests for the early detection and treatment of cancer and other serious diseases, announced that its registration on Form S-3 was declared effective Friday,...

Company reports net loss of $2.1M.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) a leader in the development of proprietary cell therapies, announced financial results for the third quarter ended March 31, 2002. Quarter highlights were led by the...

Company highlights pharmaceutical product developments at annual meeting.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- At the annual meeting of Abbott Laboratories (ABT) shareholders, chairman and CEO Miles D. White highlighted the company's scientific efforts; the successful integration of Knoll; and the performance...

Biotech companies enter into GPCR collaboration.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Alchemia Pty Ltd., an Australian chemistry and drug discovery company, and CelTor Biosystems, a U.S. biotechnology company specialized in antiinflammatory drug discovery, announced that they have...

Companies sign exclusive license agreement to develop five monoclonal antibodies.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- AltaRex Corp. (AXO.TO, ALXFF.OTC) announced that AltaRex and a wholly owned subsidiary of United Therapeutics Corp. have entered into an exclusive license agreement for the development of five...

New data supporting company's technology platform presented.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- AltaRex Corp. (AXO.TO, ALXFF.OTC) made an oral presentation at the Experimental Biology 2002 conference in New Orleans, an American Association of Immunology sponsored event. Birgit Schultes, PhD,...

Companies join forces to market anticancer compound mitomycin.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners (APPX) has entered into an exclusive sales and distribution agreement with SuperGen, Inc., (SUPG) for generic mitomycin. Mitomycin, a lyophilized product available...

Company posts strong revenues, net income for 2002 first quarter.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- American Pharmaceutical Partners, Inc., (APPX) reported financial results for the first quarter ended March 31, 2002. Total revenues in the 2002 first quarter increased 38% to $53.9 million...

First quarter 2002 earnings per share increased 14%.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Amgen (AMGN) announced that worldwide product sales increased 14% to $909 million in the first quarter of 2002, from $798 million for the first quarter last year. Earnings per share for the first...

Company reports 1Q 2002 performance.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Aradigm Corporation (ARDM) announced financial results for the first quarter ended March 31, 2002. Contract revenues for the first quarter of 2002 increased to $8.1 million from $6.7 million for...

Argenta succeeds in compound optimization project.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Argenta Discovery announced the success of a joint hit-to-lead optimization project with Aventis Pharma, the global pharmaceutical business of Aventis SA. Argenta identified two potential lead...

Three patents issued for adeno-associated virus vector technology.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Avigen, Inc., (AVGN) announced it has received three new patents, strengthening its expansive intellectual property portfolio in adeno-associated virus (AAV) vector technology. Two of the patents...

Private financing raises $46M.
June 12, 2002... 2002 JUN 12 - (NewsRx.com & NewsRx.net) -- Barrier Therapeutics, Inc., (Barrier), a new drug development company for dermatological products, has raised $46 million to create an independent biopharmaceutical company based on technology and...